文献速递白血病

干扰素α-1b、白细胞介素2联合沙利度胺逆转急性髓系白血病微小残留病的疗效

[Therapeutic effect of combined use of interferon alpha-1b, interleukin-2 and thalidomide on reversing minimal residual disease in acute myeloid leukemia].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2019-01-01

研究纳入18例血液学完全缓解但微小残留病(MRD)阳性的急性髓系白血病(AML)患者,接受不同剂量干扰素α-1b、白细胞介素2联合沙利度胺(「干白沙」方案)治疗并监测MRD。常规剂量治疗1~2个月后7例MRD转阴、3例明显下降;总有效率72.2%,治疗前MRD<1.0%者有效率81.8%(9/11),MRD≥1.0%者57.1%(4/7)。结论认为该方案可使MRD转阴或下降,增加剂量后疗效增加,疗效与治疗前MRD水平可能呈负相关。

要点

  • 18例血液学缓解但MRD阳性的AML患者接受「干白沙」方案治疗,总有效率72.2%。
  • 常规剂量治疗1~2个月后7例MRD转阴、3例明显下降,3例MRD升高(其中5例复发)。
  • MRD≥1.0%者有效率57.1%(4/7),MRD<1.0%者81.8%(9/11)。

核心结论

  • 「干白沙」方案可使血液学完全缓解但MRD阳性的AML患者MRD转阴或下降。
  • 增加方案药物剂量后疗效增加,疗效与治疗前MRD水平可能呈负相关。

研究设计与样本

  • 对2016年7月至2018年6月收治的18例(17例来自郑州大学附属肿瘤医院,1例来自平顶山市第一人民医院)血液学完全缓解但MRD阳性的AML患者应用不同剂量的「干白沙」方案,监测MRD水平变化。

主要发现

  • 18例患者接受常规剂量「干白沙」方案1~2个月,7例患者MRD转阴,3例患者MRD水平明显下降,3例MRD水平升高,5例复发。
  • MRD水平升高的3例患者接受加量的「干白沙」方案,2例MRD转阴,1例MRD水平下降。
  • 「干白沙」方案干预治疗MRD阳性AML总有效率为72.2%。
  • 治疗前MRD≥1.0%的患者有效率为57.1%(4/7),MRD<1.0%的患者有效率为81.8%(9/11)。

关键数值与推荐

  • 总有效率72.2%。
  • MRD≥1.0%的患者有效率57.1%(4/7),MRD<1.0%的患者有效率81.8%(9/11)。

临床怎么用

  • 原文结论认为「干白沙」方案可使血液学完全缓解但MRD阳性的AML患者MRD转阴或下降,增加方案药物剂量后疗效增加,疗效与治疗前MRD水平可能呈负相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore the effect of combination regimen of interferon alpha-1b, interleukin-2 and thalidomide (ITI regimen) on minimal residual disease (MRD) in patients with acute myeloid leukemia (AML) who were in hematologic remission but MRD-positive. Methods: Eighteen patients (17 from Tumor Hospital of Zhengzhou University and 1 from the First People's Hospital of Pingdingshan City) with AML admitted from July 2016 to June 2018, who were in hematologic remission but MRD-positive were treated with different doses of ITI regimen, and the MRD levels were monitored. Results: Among 18 patients who received a conventional dose of ITI regimen for 1 to 2 months, 7 patients had undetectable MRD, 3 had significant decrease in MRD levels, 3 had elevated MRD level and had hematologic recurrence. Three patients with elevated MRD level received a higher dose of ITI regimen, 2 of them turned to MRD negative and the other 1 patient had decreased MRD level. The total response rate was 72.2%, and the response rate in patients with MRD > 1.0% was 57.1% (4/7) , and that of patients with MRD < 1.0% was 81.8% (9/11) , respectively. Conclusion: The ITI regimen can reduce the MRD level of patient with AML who are in hematologic remission but MRD-positive. The therapeutic effect could be improved by a higher dose administration of ITI regimen, and therapeutic effect may be negatively correlated with MRD level before treatment. 目的: 探讨干扰素α-1b、白细胞介素2联合沙利度胺("干白沙"方案)对急性髓系白血病(AML)患者微小残留病(MRD)的影响。 方法: 对2016年7月至2018年6月收治的18例(17例来自郑州大学附属肿瘤医院,1例来自平顶山市第一人民医院)处于血液学完全缓解但MRD阳性的AML患者应用不同剂量的"干白沙"方案,监测其MRD水平变化。 结果: 18例患者接受常规剂量"干白沙"方案1~2个月,7例患者MRD转阴,3例患者MRD水平明显下降,3例MRD水平升高,5例复发。MRD水平升高的3例患者接受加量的"干白沙"方案,2例MRD转阴,1例MRD水平下降。"干白沙"方案干预治疗MRD阳性AML总有效率为72.2%。根据治疗前MRD水平分组,MRD≥1.0%的患者有效率为57.1%(4/7),MRD<1.0%的患者有效率为81.8%(9/11)。 结论: "干白沙"方案可使血液学完全缓解但MRD阳性的AML患者MRD转阴或下降,增加方案药物剂量后疗效增加,疗效与治疗前MRD水平可能呈负相关。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Mi RH, Chen L, Wei XD, et al. [Therapeutic effect of combined use of interferon alpha-1b, interleukin-2 and thalidomide on reversing minimal residual disease in acute myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2019. PMID: 30831625. doi:10.3760/cma.j.issn.0253-2727.2019.02.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。